FDA draft guidance addresses use of external controls to assess effectiveness of new drugs and biologics
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesClinical TrialsComplianceNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyResearch, Design and Development